Glycobiology of immune responses

Annals of the New York Academy of Sciences

Volumn 1253, Issue 1, 2012, Pages 1-15

  Rabinovich, Gabriel A ^a,b   van Kooyk, Yvette ^c   Cobb, Brian A ^d  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C type lectins; Galectins; Glycans; Glycobiology; Glycoimmunology; Lectins; Siglecs

Indexed keywords

BINDING PROTEIN; CARBOHYDRATE; GALECTIN; GLYCAN; GLYCAN BINDING PROTEIN; GLYCOPROTEIN; LECTIN; LIPID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NUCLEIC ACID; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CHRONIC INFLAMMATION; GLYCOBIOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNE SYSTEM; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; TUMOR IMMUNITY;

EID: 84860252480     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06492.x     Document Type: Review

References (117)

1. Levine, M.J., M.S. Reddy, L.A. Tabak, et al. 1987. Structural aspects of salivary glycoproteins. J. Dent. Res. 66: 436-441.
2. Brockhausen, I., H. Schachter & P. Stanley. 2009. O-GalNAc Glycans. In Essentials of Glycobiology. A. Varki, R.D. Cummings, J.D. Esko, H.H. Freeze, P. Stanley, C.R. Bertozzi, G.W. Hart & M.E. Etzler, Eds.: 115-127. Cold Spring Harbor Cold Spring Harbor Laboratory Press.
3. Stanley, P., H. Schachter & N. Taniguchi. 2009. N-Glycans. In Essentials of Glycobiology. A. Varki, R.D. Cummings, J.D. Esko, H.H. Freeze, P. Stanley, C.R. Bertozzi, G.W. Hart & M.E. Etzler, Eds.: 101-114. Cold Spring Harbor Cold Spring Harbor Laboratory Press.
4. Nothaft, H. & C.M. Szymanski. 2010. Protein glycosylation in bacteria: sweeter than ever. Nat. Rev. Microbiol. 8: 765-778.
5. Theodore, M. & E. Morava. 2011. Congenital disorders of glycosylation: sweet news. Curr. Opin. Pediatr. 23: 581-587.
6. Van Geet, C., J. Jaeken, K. Freson, et al. 2001. Congenital disorders of glycosylation type Ia and IIa are associated with different primary haemostatic complications. J. Inherit. Metab Dis. 24: 477-492.
7. Wang, Y., J. Tan, M. Sutton-Smith, et al. 2001. Modeling human congenital disorder of glycosylation type IIa in the mouse: conservation of asparagine-linked glycan-dependent functions in mammalian physiology and insights into disease pathogenesis. Glycobiology 11: 1051-1070.
8. Ohtsubo, K. & J.D. Marth. 2006. Glycosylation in cellular mechanisms of health and disease. Cell 126: 855-866.
9. Takahashi, M., Y. Kuroki, K. Ohtsubo & N. Taniguchi. 2009. Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins. Carbohydr. Res. 344: 1387-1390.
10. Oberg, F., J. Sjohamn, G. Fischer, et al. 2011. Glycosylation increases the thermostability of human aquaporin 10 protein. J. Biol. Chem. 286: 31915-31923.
11. Garner, O.B. & L.G. Baum. 2008. Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling. Biochem. Soc. Trans. 36: 1472-1477.
12. Boscher, C., J.W. Dennis & I.R. Nabi. 2011. Glycosylation, galectins and cellular signaling. Curr. Opin. Cell. Biol. 23: 383-392.
13. Li, Y., H. Li, N. Dimasi, et al. 2001. Crystal structure of a superantigen bound to the high-affinity, zinc-dependent site on MHC class II. Immunity 14: 93-104.
14. Dai, S., G.A. Murphy, F. Crawford, et al. 2010. Crystal structure of HLA-DP2 and implications for chronic beryllium disease. Proc. Natl. Acad. Sci. USA 107: 7425-7430.
15. Harrison, R.L. & D.L. Jarvis. 2006. Protein N-glycosylation in the baculovirus-insect cell expression system and engineering of insect cells to produce "mammalianized" recombinant glycoproteins. Adv. Virus Res. 68: 159-191.
16. Blixt, O., S. Head, T. Mondala, et al. 2004. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc. Natl. Acad. Sci. USA 101: 17033-17038.
17. Comelli, E.M., S.R. Head, T. Gilmartin, et al. 2006. A focused microarray approach to functional glycomics: transcriptional regulation of the glycome. Glycobiology 16: 117-131.
18. Demetriou, M., M. Granovsky, S. Quaggin & J.W. Dennis. 2001. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409: 733-739.
19. Ryan, S.O., J.A. Bonomo, F. Zhao & B.A. Cobb. 2011. MHCII glycosylation modulates Bacteroides fragilis carbohydrate antigen presentation. J. Exp. Med. 208: 1041-1053.
20. Amith, S.R., P. Jayanth, S. Franchuk, et al. 2009. Dependence of pathogen molecule-induced toll-like receptor activation and cell function on Neu1 sialidase. Glycoconj. J. 26: 1197-1212.
21. Amith, S.R., P. Jayanth, S. Franchuk, et al. 2010. Neu1 desialylation of sialyl alpha-2, 3-linked beta-galactosyl residues of TOLL-like receptor 4 is essential for receptor activation and cellular signaling. Cell Signal. 22: 314-324.
22. van Kooyk, Y. & T.B. Geijtenbeek. 2003. DC-SIGN: escape mechanism for pathogens. Nat. Rev. Immunol. 3: 697-709.
23. Andersson, K.B., K.E. Draves, D.M. Magaletti, et al. 1996. Characterization of the expression and gene promoter of CD22 in murine B cells. Eur. J. Immunol. 26: 3170-3178.
24. O'Reilly, M.K., H. Tian & J.C. Paulson. 2011. CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells. J. Immunol. 186: 1554-1563.
25. Liu, F.T. & G.A. Rabinovich. 2010. Galectins: regulators of acute and chronic inflammation. Ann. N. Y. Acad. Sci. 1183: 158-182.
26. Anthony, R.M., T. Kobayashi, F. Wermeling & J.V. Ravetch. 2011. Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway. Nature 475: 110-113.
27. Kaneko, Y., F. Nimmerjahn & J.V. Ravetch. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673.
28. Matsushita, M. 2010. Ficolins: complement-activating lectins involved in innate immunity. J. Innate. Immun. 2: 24-32.
29. Stanley, P. & T. Okajima. 2010. Roles of glycosylation in Notch signaling. Curr. Top. Dev. Biol. 92: 131-164.
30. Lowe, J.B. 2003. Glycan-dependent leukocyte adhesion and recruitment in inflammation. Curr. Opin. Cell Biol. 15: 531-538.
31. Mitoma, J., X. Bao, B. Petryanik, et al. 2007. Critical functions of N-glycans in L-selectin-mediated lymphocyte homing and recruitment. Nat. Immunol. 8: 409-418.
32. Pashov, A., S. Garimalla, B. Monzavi-Karbassi & T. Kieber-Emmons. 2009. Carbohydrate targets in HIV vaccine research: lessons from failures. Immunotherapy 1: 777-794.
33. Krinos, C.M., M.J. Coyne, K.G. Weinacht, et al. 2001. Extensive surface diversity of a commensal microorganism by multiple DNA inversions. Nature 414: 555-558.
34. Carlin, A.F., A.L. Lewis, A. Varki & V. Nizet. 2007. Group B streptococcal capsular sialic acids interact with siglecs (immunoglobulin-like lectins) on human leukocytes. J. Bacteriol. 189: 1231-1237.
35. van Kooyk, Y. & G.A. Rabinovich. 2008. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat. Immunol. 9: 593-601.
36. Drickamer, K. 1999. C-type lectin-like domains. Curr. Opin. Struct. Biol. 9: 585-590.
37. Figdor, C.G., Y. van Kooyk & G.J. Adema. 2002. C-type lectin receptors on dendritic cells and Langerhans cells. Nat. Rev. Immunol. 2: 77-84.
38. Kawasaki, T., M. Li, Y. Kozutsumi & I. Yamashina. 1986. Isolation and characterization of a receptor lectin specific for galactose/N-acetylgalactosamine from macrophages. Carbohydr. Res. 151: 197-206.
39. van Vliet, S.J., E. Saeland & Y. van Kooyk. 2008. Sweet preferences of MGL:carbohydrate specificity and function. Trends Immunol. 29: 83-90.
40. Zelensky, A.N. & J.E. Gready. 2005. The C-type lectin-like domain superfamily. FEBS J. 272: 6179-6217.
41. Engering, A., T.B. Geijtenbeek, S.J. van Vliet, et al. 2002.The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J. Immunol. 168: 2118-26.
42. Unger, W.W.J. & Y. van Kooyk. 2011. Dressed for success; C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells. Curr. Opin Immunol. 23: 131-137.
43. Birkholz, K., M. Schwenkert, C. Kellner, et al. 2010. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood 116: 2277-2285.
44. Singh, S.K., J. Stephani, M. Schaefer, et al. 2009a. Targeting of glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. Mol. Immunol. 47: 164-174.
45. Idoyaga, J., C. Cheong, K. Suda, et al. 2008. Langerin/CD207 receptor on dendritic cells mediates efficiënt antigen presentation of non MHC I and II products in vivo. J. Immunol. 180: 3647-3650.
46. Bozzacco, L., C. Trumpfheller, F.P. Siegal, et al. 2007. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc. Natl. Acad. Sci. USA 104: 1289-1294.
47. Sancho, D., Mourao-Sa, D., Joffre, O.P., et al. 2008. Tumor therapy in mice via antigen targeting to a novel DC restricted C-type lectin. J. Clin. Invest. 118: 2098-2110.
48. Osorio, F. & C. Reis e Sousa. 2011. Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity 34: 651-664.
49. Park, C.G., K. Takahara, E. Umemoto, et al. 2001. Five mouse homologues of the human dendritic cell C-type lectin, DC-SIGN. Int. Immunol. 13: 1283-1290.
50. Singh, S.K., I. Streng-Ouwehand, M. Litjens, et al. 2009b. Characterization of murine MGL 1 and MGL 2 C-type lectins: Distinct glycan specificities and tumor binding properties. Mol. immunol. 46: 1240-1249.
51. Denda-Nagai, K., S. Aida, K. Saba, et al. 2010. Distribution and function of macrophage galactose-type C-type lectin 2 (MGL2/CD301b): efficient uptake and presentation of glycosylated antigens by dendritic cells. J. Biol. Chem. 285: 19193-19204.
52. Brown, G.D. 2006. Dectin-1: a signaling non-TLR pattern-recognition receptor. Nat. Rev. Immunol. 6: 33-43.
53. Van Die, I. & R.D. Cummings. 2010. Glycan mimmickry by parasitic helminths: a strategy for modulating the host immune response? Glycobiology 20: 2-12.
54. Gow, N.A.R., F.L. van de Veerdonk, A.J.P. Brown & M.G. Netea. 2012. Candida albicans morphogenesis and host defense: discriminating invasion from colonization. Nat. Rev. Microbiol. 10: 112-122.
55. Aarnoudse, C.A., M. Bax, M. Sánchez-Hernández, et al. 2008. Glycan modification of the tumor antigen gp100 targets DC-SIGN to enhance dendritic cell induced antigen presentation to T cells. Int. J. Cancer 122: 839-46.
56. Gringhuis, S.I., J. van Dunnen, M. Litjens, et al. 2007. C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB. Immunity 26: 605-616.
57. Gringhuis, S.I., J. den Dunnen, M. Litjens, et al. 2009. Carbohydrate-specific signalling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat. Immunol. 10: 1081-1088.
58. Geijtenbeek, T.B. & S.I. Gringhuis. 2009. Signalling through C-type lectin receptors: shaping immune responses. Nat. Rev. Immunol. 9: 465-479.
59. Geijtenbeek, T.B.H., S.J. van Vliet, A. Engering, et al. 2003. Self- and non-self recognition by C-type lectins on dendritic cells. Ann. Rev. Immunol. 22: 33-54.
60. Dam, T.K. & C.F. Brewer. 2010. Lectins as pattern recognition molecules: the effects of epitope density in innate immunity. Glycobiology 20: 270-279.
61. van Gisbergen, K.P.J.M., C.A. Aarnoudse, G.A. Meijer, et al. 2005a. Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin. Cancer Res. 65: 5935-5943.
62. Saeland, E., S.J. van Vliet, M. Bäckström, et al. 2007. The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol. Immunother. 56: 1225-1236.
63. Geijtenbeek, T.B.H., D.S. Kwon, R. Torensma, et al. 2000. DC-SIGN, a dendritic cell specific HIV-1 binding protein that enhances trans-infection of T cells. Cell 100: 587-597.
64. de Witte, L., A. Nabatov, M. Prion, et al. 2007. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat. Med. 13: 367-371.
65. Lambert, A.A., C. Gilbert, M. Richard, et al. 2008. The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways. Blood 112: 1299-1307.
66. Garcia-Vallejo, J.J. & Y. van Kooyk. 2009. Endogenous ligands for C-type lectin receptors: the true regulators of immune homeostatis. Immunol. Rev. 230: 22-37.
67. van Gisbergen, K.P.J.M., M. Sanchez-Hernandez, T.B. Geijtenbeek, & Y. van Kooyk. 2005b. Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. J. Exp. Med. 201: 1281-1292.
68. van Vliet, S.J., S.I. Gringhuis, T.B. Geijtenbeek & Y. van Kooyk. 2006. Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45. Nat. Immunol. 24: 1200-1208.
69. Crocker, P.R., J.C. Paulson & A. Varki. 2007. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7: 255-266.
70. O'Reilly, M.K. & J.C. Paulson. 2009. Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol. Sci. 30: 240-248.
71. Angata, T. & A. Varki. 2002. Chemical diversity in the sialic acids and related alpha-keto acids: an evolutionary perspective. Chem. Rev. 102: 439-469.
72. Avril, T., E.R. Wagner, H.J. Willison & P.R. Crocker. 2006. Sialic acid-binding immunoglobulin-like lectin 7 mediates selective recognition of sialylated glycans expressed on Campylobacter jejuni lipooligosaccharides. Infect. Immun. 74: 4133-4141.
73. Paul, S.P., L.S. Taylor, E.K. Stansbury & D.W. McVicar. 2000. Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 96: 483-490.
74. Liu, Y., G.Y. Chen & P. Zheng. 2009. CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns. Trends Immunol. 30: 557-561.
75. Blasius, A.L. & M. Colonna. 2006. Sampling and signaling in plasmacytoid dendritic cells: the potential roles of Siglec-H. Trends Immunol. 27: 255-260.
76. Rabinovich, G.A. & M.A. Toscano. 2009. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat. Rev. Immunol. 9: 338-352.
77. Di Lella, S., V. Sundblad, J.P. Cerliani, et al. 2011. When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry 50: 7842-7857.
78. Sato, S., C. St-Pierre, P. Bhaumik & J. Nieminen. 2009. Galectins in innate immunity: dual functions of host soluble beta-galactoside-binding lectins as damage-associated molecular patterns (DAMPs) and as receptors for pathogen-associated molecular patterns (PAMPs). Immunol. Rev. 230: 172-187.
79. Brewer, C.F., M.C. Miceli & L.G. Baum. 2002. Clusters, bundles, arrays and lattices: novel mechanisms for lectin-saccharide-mediated cellular interactions. Curr. Opin. Struct. Biol. 12: 616-623.
80. Toscano, M.A., G.A. Bianco, J.M. Ilarregui, et al. 2007. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol. 8: 825-834.
81. Zhu, C., A.C. Anderson, A. Schubart, et al. 2005. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6: 1245-1252.
82. Cooper, D., J.M. Ilarregui, S.A. Pesoa, et al. 2010. Multiple functional targets of the immunoregulatory activity of galectin-1: control of immune cell trafficking, dendritic cell physiology, and T-cell fate. Methods Enzymol. 480: 199-244.
83. Jiang, H.R., Z. Al Rasebi, E. Mensah-Brown, et al. 2009. Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J. Immunol. 182: 1167-1173.
84. Forsman, H., U. Islander, E. Andréasson, et al. 2011. Galectin 3 aggravates joint inflammation and destruction in antigen-induced arthritis. Arthritis Rheum. 63: 445-454.
85. Dube, D.H. & C.R. Bertozzi. 2005. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. 4: 477-488.
86. Sperandio, M., C.A. Gleissner & K. Ley. 2009. Glycosylation in immune cell trafficking. Immunol. Rev. 230: 97-113.
87. Buzás, E.I., B. György, M. Pásztói, et al. 2006. Carbohydrate recognition systems in autoimmunity. Autoimmunity 39: 691-704.
88. Grigorian, A., L. Araujo, N.N. Naidu, et al. 2011. N-acetylglucosamine inhibits T-helper 1 (Th1)/T-helper 17 (Th17) cell responses and treats experimental autoimmune encephalomyelitis. J. Biol. Chem. 286: 40133-40141.
89. Green, R.S., E.L. Stone, M. Tenno, et al. 2007. Mammalian N-glycan branching protects against innate immune self-recognition and inflammation in autoimmune disease pathogenesis. Immunity 27: 308-320.
90. Hiki, Y., H. Odani, M. Takahashi, et al. 2001. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int. 59: 1077-1085.
91. Padler-Karavani, V., H. Yu, H. Cao, et al. 2008. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology 18: 818-830.
92. Ju, T. & R.D. Cummings. 2005. Protein glycosylation: chaperone mutation in Tn syndrome. Nature 437: 1252.
93. Ilarregui, J.M., D.O. Croci, G.A. Bianco, et al. 2009. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 10: 981-991.
94. Kel, J., J. Oldenampsen, M. Luca, et al. 2007. Soluble mannosylated myelin peptide inhibits the encephalitogenicity of autoreactive T cells during experimental autoimmune encephalomyelitis. Am. J. Pathol. 170: 272-280.
95. Zhou, Y., H. Kawasaki, S.C. Hsu, et al. 2010. Oral tolerance to food-induced systemic anaphylaxis mediated by the C-type lectin SIGNR1. Nat. Med. 16: 1128-1133.
96. Jellusova, J., U. Wellmann, K. Amann, et al. 2010. CD22 x Siglec-G double-deficient mice have massively increased B1 cell numbers and develop systemic autoimmunity. J. Immunol. 184: 3618-3627.
97. Saeland, E., A.I. Belo, S. Mongera, et al. 2011. Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients. Int. J. Cancer. Aug 5. doi:. [Epub ahead of print].
98. Bozzacco, L., C. Trumpfheller, Y. Huang, et al. 2010. HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC. Eur. J. Immunol. 40: 36-46.
99. Klechevsky, E., A.L. Flamar, Y. Cao, et al. 2010. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 116: 1685-1697.
100. Singh, S.K., I. Streng-Ouwehand, M. Litjens, et al. 2011. Design of neo-glycoconjugates that target the Mannose Receptor and enhance TLR independent cross-presentation and Th1 polarization. Eur. J. Immunol. 41: 916-25.
101. Burgdorf, S., V. Lukacs-Kornek & C. Kurtc. 2006. The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. J. Immunol. 176: 6770-6776.
102. Caminischi, I., A.I. Proietto, F. Ahmet, et al. 2008. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 112: 3264-3273.
103. Sánchez-Navarro, M. & J. Rojo. 2010. Targeting DC-SIGN with carbohydrate multivalent systems. Drug News Perspect 23: 557-572.
104. Streng-Ouwehand, I., W.W.J. Unger & Y. van Kooyk. 2011. C-type lectin receptors for tumor eradication: future directions. Cancers 3: 3169-3188.
105. Salatino, M. & G.A. Rabinovich. 2011. Fine-tuning antitumor responses through the control of galectin-glycan interactions: an overview. Methods Mol. Biol. 677: 355-374.
106. Rubinstein, N., M. Alvarez, N.W. Zwirner, et al. 2004. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5: 241-251.
107. Cedeno-Laurent, F., M.J. Opperman, S.R. Barthel, et al. 2012. Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity. J. Invest. Dermatol. 132: 410-420.
108. Juszczynski, P., J. Ouyang, S. Monti, et al. 2007. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl. Acad. Sci. USA 104: 13134-13139.
109. Banh, A., J. Zhang, H. Cao, et al. 2011. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res. 71: 4423-4431.
110. Kuo, P.L., J.Y. Hung, S.K. Huang, et al. 2011. Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway. J. Immunol. 186: 1521-1530.
111. Tang, D., Z. Yuan, X. Xue, et al. 2011. High expression of galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer. Int. J. Cancer. doi:. [Epub ahead of print.
112. Soldati, R., E. Berger, A.C. Zenclussen, et al. 2011. Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments. Int. J. Cancer. doi:. [Epub ahead of print.
113. Dardalhon, V., A.C. Anderson, J. Karman, et al. 2010. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J. Immunol. 185: 1383-1392.
114. Demotte, N., G. Wieërs, P. Van Der Smissen, et al. 2010. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res. 70: 7476-748.
115. Tsuboi, S., M. Sutoh, S. Hatakeyama, et al. 2011. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J. 30: 3173-3185.
116. Nicoll, G., T. Avril, K. Lock, et al. 2003. Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms. Eur. J. Immunol. 33: 1642-1648.
117. Ohta, M., A. Ishida, M. Toda, et al. 2010. Immunomodulation of monocyte-derived dendritic cells through ligation of tumor-produced mucins to Siglec-9. Biochem. Biophys. Res. Commun. 402: 663-669.